반려동물 알레르기 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2031년)

Persistence Market Research has recently released a comprehensive report on the global Pet Allergy Treatment Market. The report provides an in-depth analysis of key market dynamics, including drivers, trends, opportunities, and challenges, offering detailed insights into the market landscape.

Key Insights:

• Pet Allergy Treatment Market Size (2024E): USD 2,671.20 million
• Projected Market Value (2031F): USD 3,930.76 million
• Global Market Growth Rate (CAGR 2024 to 2031):5.7%

Pet Allergy Treatment Market - Report Scope:

Pet allergies represent a significant health concern for both pets and their owners globally. The market for pet allergy treatment encompasses a range of therapeutic options aimed at managing allergic reactions caused by pets, such as cats and dogs. These treatments include medications, immunotherapy, allergen avoidance strategies, and emerging biologic therapies. The market caters to veterinary clinics, hospitals, pet care centers, and homecare settings, addressing a growing demand from pet owners seeking effective allergy management solutions.

Market Growth Drivers:

The global pet allergy treatment market is driven by several factors, including increasing pet ownership, rising awareness about pet allergies, and advancements in veterinary medicine. The growing prevalence of allergic conditions among pet owners and pets alike underscores the need for effective treatment options. Technological innovations in diagnostic tools and treatment modalities further enhance market growth, improving diagnostic accuracy and treatment efficacy. Moreover, the expanding pet insurance coverage and investments in pet healthcare infrastructure contribute to market expansion.

Market Restraints:

Despite promising growth prospects, the pet allergy treatment market faces challenges related to regulatory compliance, variability in treatment outcomes, and pet owner adherence to prescribed therapies. Regulatory frameworks governing veterinary pharmaceuticals and biologics impose compliance burdens on manufacturers and healthcare providers, influencing market dynamics and operational strategies. Additionally, the high cost of advanced treatments and limited reimbursement coverage in some regions hinder market penetration, particularly in emerging economies.

Market Opportunities:

The pet allergy treatment market presents significant growth opportunities driven by demographic trends, increasing pet humanization, and evolving consumer preferences for pet healthcare products and services. The integration of telemedicine and digital health solutions facilitates remote consultations and enhances pet owner access to veterinary care. Furthermore, collaborations between veterinary pharmaceutical companies, pet food manufacturers, and allergy specialists foster innovation in treatment protocols and allergen management strategies. Strategic investments in research and development, along with educational initiatives targeting pet owners and veterinary professionals, are essential to capitalize on emerging market opportunities.

Key Questions Answered in the Report:

• What factors are driving the growth of the pet allergy treatment market globally?
• Which treatment modalities and diagnostic tools are gaining traction among pet owners and veterinary professionals?
• How are technological advancements reshaping the competitive landscape of the pet allergy treatment market?
• Who are the key players contributing to the pet allergy treatment market, and what strategies are they employing to maintain market leadership?
• What are the emerging trends and future prospects in the global pet allergy treatment market?

Competitive Intelligence and Business Strategy:

Leading players in the global pet allergy treatment market, including pharmaceutical companies, veterinary clinics, and biotechnology firms, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop novel therapies, diagnostic tests, and allergen management solutions, catering to diverse pet owner preferences and clinical needs. Collaborations with pet healthcare providers, regulatory agencies, and pet insurance companies facilitate market access and promote technology adoption. Moreover, emphasis on evidence-based practice, veterinary education, and pet owner engagement enhances treatment outcomes and supports sustainable market growth in the evolving landscape of pet allergy management.

Key Companies Profiled:

• Zoetis Animal Healthcare
• Merck and Co Inc.
• Boehringer Ingelheim GmbH
• Elanco Animal Health Incorporated
• Bayer AG
• Vetoquinol S.A.
• Dechra Pharmaceuticals PLC
• Virbac SA
• IDEXX Laboratories, Inc.
• Ceva Sante Animale
• Kindred Biosciences, Inc.
• Phirbo Animal Health
• Norbrook Laboratories Limited
• Vetiquinol SA
• Neogen Corporation
• PetIQ, Inc.
• Huvepharma AD

Key Segments of Pet Allergy Treatment Industry Research

By Drug Class:

• Antihistamines
• Corticosteroids
• Immunotherapy
• Antibiotics

By Indication:

• Allergic Dermatitis
• Food Allergy
• Fleabite Allergy
• Contact Allergy

By Pet Type:

• Dogs
• Cats
• Rodents & Rabbits

By Route of Administration:

• Oral
• Injectable
• Topical

By Distribution Channel:

• Veterinary Hospitals
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand-side Trends
• 1.3. Supply-side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Innovation / Development Trends

4. Value Added Insights

• 4.1. Product Adoption Analysis
• 4.2. Product USPs/Features Analysis, By Brands
• 4.3. Regulatory Landscape, By Country
• 4.4. Recent Product Approval/Launches
• 4.5. Disease Epidemiology
• 4.6. Porter's Analysis
• 4.7. PESTLE Analysis
• 4.8. Value Chain Analysis
• 4.9. Unmet Needs

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global Healthcare Expenditure Outlook
  • 5.1.2. Global Pharmaceutical Market Outlook
  • 5.1.3. Global Animal Healthcare Market Outlook
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Rising Rate of Pet Adoption
  • 5.2.2. Increase in Research and Development
  • 5.2.3. Strategic Collaborations among players
  • 5.2.4. Cost of Product
  • 5.2.5. Business Expansions
  • 5.2.6. Frequency of Product Approval
  • 5.2.7. Pet Care Insurance
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. Global Market Demand (in Value or Size in US$ Million) Analysis 2019-2023 and Forecast, 2024-2031

• 6.1. Historical Market Value (US$ Million) Analysis, 2019-2023
• 6.2. Current and Future Market Size (US$ Million) Projections, 2024-2031
  • 6.2.1. Y-o-Y Growth Trend Analysis
  • 6.2.2. Absolute $ Opportunity Analysis
• 6.3. Revenue Opportunity Scenario- Likely/Conservative/Optimistic

7. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Drug Class

• 7.1. Introduction / Key Findings
• 7.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2019-2023
• 7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2024-2031
  • 7.3.1. Antihistamines
  • 7.3.2. Corticosteroids
  • 7.3.3. Immunotherapy
  • 7.3.4. Antibiotics
• 7.4. Market Attractiveness Analysis By Drug Class

8. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Indication

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Million) Analysis By Indication, 2019-2023
• 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2024-2031
  • 8.3.1. Allergic Dermatitis
  • 8.3.2. Food Allergy
  • 8.3.3. Fleabite Allergy
  • 8.3.4. Contact Allergy
• 8.4. Market Attractiveness Analysis By Indication

9. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Pet Type

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Million) Analysis By Pet Type, 2019-2023
• 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Pet Type, 2024-2031
  • 9.3.1. Dogs
  • 9.3.2. Cats
  • 9.3.3. Rodents and rabbits
• 9.4. Market Attractiveness Analysis By Pet Type

10. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Route of Administration

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Million) Analysis By Route of Administration, 2019-2023
• 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2024-2031
  • 10.3.1. Oral
  • 10.3.2. Injectable
  • 10.3.3. Topical
• 10.4. Market Attractiveness Analysis By Route of Administration

11. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Distribution Channel

• 11.1. Introduction / Key Findings
• 11.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2019-2023
• 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2024-2031
  • 11.3.1. Veterinary Hospitals
  • 11.3.2. Retail Pharmacies
  • 11.3.3. Online Pharmacies
  • 11.3.4. Others
• 11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Market Analysis 2019-2023 and Forecast 2024-2031, by Region

• 12.1. Introduction / Key Findings
• 12.2. Historical Market Size (US$ Million) Analysis By Region, 2019-2023
• 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2024-2031
  • 12.3.1. North America
  • 12.3.2. Latin America
  • 12.3.3. Europe
  • 12.3.4. South Asia
  • 12.3.5. East Asia
  • 12.3.6. Oceania
  • 12.3.7. Middle East and Africa
• 12.4. Market Attractiveness Analysis By Region

13. North America Market Analysis 2019-2023 and Forecast 2024-2031

• 13.1. Introduction / Key Findings
• 13.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
  • 13.3.1. By Country
    • 13.3.1.1. United States
    • 13.3.1.2. Canada
  • 13.3.2. By Drug Class
  • 13.3.3. By Indication
  • 13.3.4. By Pet Type
  • 13.3.5. By Route of Administration
  • 13.3.6. By Distribution Channel
• 13.4. Market Attractiveness Analysis By Region
  • 13.4.1. By Country
  • 13.4.2. By Drug Class
  • 13.4.3. By Indication
  • 13.4.4. By Pet Type
  • 13.4.5. By Route of Administration
  • 13.4.6. By Distribution Channel
• 13.5. Market trends
• 13.6. Key Market Participants - Intensity Mapping
• 13.7. Drivers and Restraints - Impact Analysis
• 13.8. Country Level Analysis & Forecast
  • 13.8.1. United States Market Analysis
    • 13.8.1.1. Introduction
    • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.1.2.1. By Drug Class
      • 13.8.1.2.2. By Indication
      • 13.8.1.2.3. By Pet Type
      • 13.8.1.2.4. By Route of Administration
      • 13.8.1.2.5. By Distribution Channel
  • 13.8.2. Canada Market Analysis
    • 13.8.2.1. Introduction
    • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.2.2.1. By Drug Class
      • 13.8.2.2.2. By Indication
      • 13.8.2.2.3. By Pet Type
      • 13.8.2.2.4. By Route of Administration
      • 13.8.2.2.5. By Distribution Channel

14. Latin America Market Analysis 2019-2023 and Forecast 2024-2031

• 14.1. Introduction / Key Findings
• 14.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
  • 14.3.1. By Country
    • 14.3.1.1. Brazil
    • 14.3.1.2. Mexico
    • 14.3.1.3. Argentina
    • 14.3.1.4. Rest of Latin America
  • 14.3.2. By Drug Class
  • 14.3.3. By Indication
  • 14.3.4. By Pet Type
  • 14.3.5. By Route of Administration
  • 14.3.6. By Distribution Channel
• 14.4. Market Attractiveness Analysis By Region
  • 14.4.1. By Country
  • 14.4.2. By Drug Class
  • 14.4.3. By Indication
  • 14.4.4. By Pet Type
  • 14.4.5. By Route of Administration
  • 14.4.6. By Distribution Channel
• 14.5. Market trends
• 14.6. Key Market Participants - Intensity Mapping
• 14.7. Drivers and Restraints - Impact Analysis
• 14.8. Country Level Analysis & Forecast
  • 14.8.1. Brazil Market Analysis
    • 14.8.1.1. Introduction
    • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.1.2.1. By Drug Class
      • 14.8.1.2.2. By Indication
      • 14.8.1.2.3. By Pet Type
      • 14.8.1.2.4. By Route of Administration
      • 14.8.1.2.5. By Distribution Channel
  • 14.8.2. Mexico Market Analysis
    • 14.8.2.1. Introduction
    • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.2.2.1. By Drug Class
      • 14.8.2.2.2. By Indication
      • 14.8.2.2.3. By Pet Type
      • 14.8.2.2.4. By Route of Administration
      • 14.8.2.2.5. By Distribution Channel
  • 14.8.3. Argentina Market Analysis
    • 14.8.3.1. Introduction
    • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.3.2.1. By Drug Class
      • 14.8.3.2.2. By Indication
      • 14.8.3.2.3. By Pet Type
      • 14.8.3.2.4. By Route of Administration
      • 14.8.3.2.5. By Distribution Channel

15. Europe Market Analysis 2019-2023 and Forecast 2024-2031

• 15.1. Introduction / Key Findings
• 15.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
  • 15.3.1. By Country
    • 15.3.1.1. Germany
    • 15.3.1.2. France
    • 15.3.1.3. Spain
    • 15.3.1.4. Russia
    • 15.3.1.5. Italy
    • 15.3.1.6. BENELUX
    • 15.3.1.7. United Kingdom
    • 15.3.1.8. Rest of Europe
  • 15.3.2. By Drug Class
  • 15.3.3. By Indication
  • 15.3.4. By Pet Type
  • 15.3.5. By Route of Administration
  • 15.3.6. By Distribution Channel
• 15.4. Market Attractiveness Analysis By Region
  • 15.4.1. By Country
  • 15.4.2. By Drug Class
  • 15.4.3. By Indication
  • 15.4.4. By Pet Type
  • 15.4.5. By Route of Administration
  • 15.4.6. By Distribution Channel
• 15.5. Market trends
• 15.6. Key Market Participants - Intensity Mapping
• 15.7. Drivers and Restraints - Impact Analysis
• 15.8. Country Level Analysis & Forecast
  • 15.8.1. Germany Market Analysis
    • 15.8.1.1. Introduction
    • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.1.2.1. By Drug Class
      • 15.8.1.2.2. By Indication
      • 15.8.1.2.3. By Pet Type
      • 15.8.1.2.4. By Route of Administration
      • 15.8.1.2.5. By Distribution Channel
  • 15.8.2. France Market Analysis
    • 15.8.2.1. Introduction
    • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.2.2.1. By Drug Class
      • 15.8.2.2.2. By Indication
      • 15.8.2.2.3. By Pet Type
      • 15.8.2.2.4. By Route of Administration
      • 15.8.2.2.5. By Distribution Channel
  • 15.8.3. Spain Market Analysis
    • 15.8.3.1. Introduction
    • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.3.2.1. By Drug Class
      • 15.8.3.2.2. By Indication
      • 15.8.3.2.3. By Pet Type
      • 15.8.3.2.4. By Route of Administration
      • 15.8.3.2.5. By Distribution Channel
  • 15.8.4. Russia Market Analysis
    • 15.8.4.1. Introduction
    • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.4.2.1. By Drug Class
      • 15.8.4.2.2. By Indication
      • 15.8.4.2.3. By Pet Type
      • 15.8.4.2.4. By Route of Administration
      • 15.8.4.2.5. By Distribution Channel
  • 15.8.5. Italy Market Analysis
    • 15.8.5.1. Introduction
    • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.5.2.1. By Drug Class
      • 15.8.5.2.2. By Indication
      • 15.8.5.2.3. By Pet Type
      • 15.8.5.2.4. By Route of Administration
      • 15.8.5.2.5. By Distribution Channel
  • 15.8.6. BENELUX Market Analysis
    • 15.8.6.1. Introduction
    • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.6.2.1. By Drug Class
      • 15.8.6.2.2. By Indication
      • 15.8.6.2.3. By Pet Type
      • 15.8.6.2.4. By Route of Administration
      • 15.8.6.2.5. By Distribution Channel
  • 15.8.7. United Kingdom Market Analysis
    • 15.8.7.1. Introduction
    • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.7.2.1. By Drug Class
      • 15.8.7.2.2. By Indication
      • 15.8.7.2.3. By Pet Type
      • 15.8.7.2.4. By Route of Administration
      • 15.8.7.2.5. By Distribution Channel

16. East Asia Market Analysis 2019-2023 and Forecast 2024-2031

• 16.1. Introduction / Key Findings
• 16.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
  • 16.3.1. By Country
    • 16.3.1.1. China
    • 16.3.1.2. Japan
    • 16.3.1.3. South Korea
  • 16.3.2. By Drug Class
  • 16.3.3. By Indication
  • 16.3.4. By Pet Type
  • 16.3.5. By Route of Administration
  • 16.3.6. By Distribution Channel
• 16.4. Market Attractiveness Analysis By Region
  • 16.4.1. By Country
  • 16.4.2. By Drug Class
  • 16.4.3. By Indication
  • 16.4.4. By Pet Type
  • 16.4.5. By Route of Administration
  • 16.4.6. By Distribution Channel
• 16.5. Market trends
• 16.6. Key Market Participants - Intensity Mapping
• 16.7. Drivers and Restraints - Impact Analysis
• 16.8. Country Level Analysis & Forecast
  • 16.8.1. China Market Analysis
    • 16.8.1.1. Introduction
    • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.1.2.1. By Drug Class
      • 16.8.1.2.2. By Indication
      • 16.8.1.2.3. By Pet Type
      • 16.8.1.2.4. By Route of Administration
      • 16.8.1.2.5. By Distribution Channel
  • 16.8.2. Japan Market Analysis
    • 16.8.2.1. Introduction
    • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.2.2.1. By Drug Class
      • 16.8.2.2.2. By Indication
      • 16.8.2.2.3. By Pet Type
      • 16.8.2.2.4. By Route of Administration
      • 16.8.2.2.5. By Distribution Channel
  • 16.8.3. South Korea Market Analysis
    • 16.8.3.1. Introduction
    • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.3.2.1. By Drug Class
      • 16.8.3.2.2. By Indication
      • 16.8.3.2.3. By Pet Type
      • 16.8.3.2.4. By Route of Administration
      • 16.8.3.2.5. By Distribution Channel

17. South Asia Market Analysis 2019-2023 and Forecast 2024-2031

• 17.1. Introduction / Key Findings
• 17.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
  • 17.3.1. By Country
    • 17.3.1.1. India
    • 17.3.1.2. Indonesia
    • 17.3.1.3. Thailand
    • 17.3.1.4. Philippines
    • 17.3.1.5. Malaysia
    • 17.3.1.6. Vietnam
    • 17.3.1.7. Rest of South Asia
  • 17.3.2. By Drug Class
  • 17.3.3. By Indication
  • 17.3.4. By Pet Type
  • 17.3.5. By Route of Administration
  • 17.3.6. By Distribution Channel
• 17.4. Market Attractiveness Analysis By Region
  • 17.4.1. By Country
  • 17.4.2. By Drug Class
  • 17.4.3. By Indication
  • 17.4.4. By Pet Type
  • 17.4.5. By Route of Administration
  • 17.4.6. By Distribution Channel
• 17.5. Market trends
• 17.6. Key Market Participants - Intensity Mapping
• 17.7. Drivers and Restraints - Impact Analysis
• 17.8. Country Level Analysis & Forecast
  • 17.8.1. India Market Analysis
    • 17.8.1.1. Introduction
    • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.1.2.1. By Drug Class
      • 17.8.1.2.2. By Indication
      • 17.8.1.2.3. By Pet Type
      • 17.8.1.2.4. By Route of Administration
      • 17.8.1.2.5. By Distribution Channel
  • 17.8.2. Indonesia Market Analysis
    • 17.8.2.1. Introduction
    • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.2.2.1. By Drug Class
      • 17.8.2.2.2. By Indication
      • 17.8.2.2.3. By Pet Type
      • 17.8.2.2.4. By Route of Administration
      • 17.8.2.2.5. By Distribution Channel
  • 17.8.3. Thailand Market Analysis
    • 17.8.3.1. Introduction
    • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.3.2.1. By Drug Class
      • 17.8.3.2.2. By Indication
      • 17.8.3.2.3. By Pet Type
      • 17.8.3.2.4. By Route of Administration
      • 17.8.3.2.5. By Distribution Channel
  • 17.8.4. Philippines Market Analysis
    • 17.8.4.1. Introduction
    • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.4.2.1. By Drug Class
      • 17.8.4.2.2. By Indication
      • 17.8.4.2.3. By Pet Type
      • 17.8.4.2.4. By Route of Administration
      • 17.8.4.2.5. By Distribution Channel
  • 17.8.5. Malaysia Market Analysis
    • 17.8.5.1. Introduction
    • 17.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.5.2.1. By Drug Class
      • 17.8.5.2.2. By Indication
      • 17.8.5.2.3. By Pet Type
      • 17.8.5.2.4. By Route of Administration
      • 17.8.5.2.5. By Distribution Channel
  • 17.8.6. Vietnam Market Analysis
    • 17.8.6.1. Introduction
    • 17.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.6.2.1. By Drug Class
      • 17.8.6.2.2. By Indication
      • 17.8.6.2.3. By Pet Type
      • 17.8.6.2.4. By Route of Administration
      • 17.8.6.2.5. By Distribution Channel

18. Oceania Market Analysis 2019-2023 and Forecast 2024-2031

• 18.1. Introduction / Key Findings
• 18.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
• 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
  • 18.3.1. By Country
    • 18.3.1.1. Australia
    • 18.3.1.2. New Zealand
  • 18.3.2. By Drug Class
  • 18.3.3. By Indication
  • 18.3.4. By Pet Type
  • 18.3.5. By Route of Administration
  • 18.3.6. By Distribution Channel
• 18.4. Market Attractiveness Analysis By Region
  • 18.4.1. By Country
  • 18.4.2. By Drug Class
  • 18.4.3. By Indication
  • 18.4.4. By Pet Type
  • 18.4.5. By Route of Administration
  • 18.4.6. By Distribution Channel
• 18.5. Market trends
• 18.6. Key Market Participants - Intensity Mapping
• 18.7. Drivers and Restraints - Impact Analysis
• 18.8. Country Level Analysis & Forecast
  • 18.8.1. Australia Market Analysis
    • 18.8.1.1. Introduction
    • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.1.2.1. By Drug Class
      • 18.8.1.2.2. By Indication
      • 18.8.1.2.3. By Pet Type
      • 18.8.1.2.4. By Route of Administration
      • 18.8.1.2.5. By Distribution Channel
  • 18.8.2. New Zealand Market Analysis
    • 18.8.2.1. Introduction
    • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.2.2.1. By Drug Class
      • 18.8.2.2.2. By Indication
      • 18.8.2.2.3. By Pet Type
      • 18.8.2.2.4. By Route of Administration
      • 18.8.2.2.5. By Distribution Channel

19. Middle East and Africa Market Analysis 2019-2023 and Forecast 2024-2031

• 19.1. Introduction / Key Findings
• 19.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
• 19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
  • 19.3.1. By Country
    • 19.3.1.1. GCC Countries
    • 19.3.1.2. Turkey
    • 19.3.1.3. Egypt
    • 19.3.1.4. Israel
    • 19.3.1.5. South Africa
    • 19.3.1.6. Northern Africa
    • 19.3.1.7. Rest of Middle East and Africa
  • 19.3.2. By Drug Class
  • 19.3.3. By Indication
  • 19.3.4. By Pet Type
  • 19.3.5. By Route of Administration
  • 19.3.6. By Distribution Channel
• 19.4. Market Attractiveness Analysis By Region
  • 19.4.1. By Country
  • 19.4.2. By Drug Class
  • 19.4.3. By Indication
  • 19.4.4. By Pet Type
  • 19.4.5. By Route of Administration
  • 19.4.6. By Distribution Channel
• 19.5. Market trends
• 19.6. Key Market Participants - Intensity Mapping
• 19.7. Drivers and Restraints - Impact Analysis
• 19.8. Country Level Analysis & Forecast
  • 19.8.1. GCC Countries Market Analysis
    • 19.8.1.1. Introduction
    • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.1.2.1. By Drug Class
      • 19.8.1.2.2. By Indication
      • 19.8.1.2.3. By Pet Type
      • 19.8.1.2.4. By Route of Administration
      • 19.8.1.2.5. By Distribution Channel
  • 19.8.2. Turkey Market Analysis
    • 19.8.2.1. Introduction
    • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.2.2.1. By Drug Class
      • 19.8.2.2.2. By Indication
      • 19.8.2.2.3. By Pet Type
      • 19.8.2.2.4. By Route of Administration
      • 19.8.2.2.5. By Distribution Channel
  • 19.8.3. Egypt Market Analysis
    • 19.8.3.1. Introduction
    • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.3.2.1. By Drug Class
      • 19.8.3.2.2. By Indication
      • 19.8.3.2.3. By Pet Type
      • 19.8.3.2.4. By Route of Administration
      • 19.8.3.2.5. By Distribution Channel
  • 19.8.4. Israel Market Analysis
    • 19.8.4.1. Introduction
    • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.4.2.1. By Drug Class
      • 19.8.4.2.2. By Indication
      • 19.8.4.2.3. By Pet Type
      • 19.8.4.2.4. By Route of Administration
      • 19.8.4.2.5. By Distribution Channel
  • 19.8.5. South Africa Market Analysis
    • 19.8.5.1. Introduction
    • 19.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.5.2.1. By Drug Class
      • 19.8.5.2.2. By Indication
      • 19.8.5.2.3. By Pet Type
      • 19.8.5.2.4. By Route of Administration
      • 19.8.5.2.5. By Distribution Channel
  • 19.8.6. Northern Africa Market Analysis
    • 19.8.6.1. Introduction
    • 19.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.6.2.1. By Drug Class
      • 19.8.6.2.2. By Indication
      • 19.8.6.2.3. By Pet Type
      • 19.8.6.2.4. By Route of Administration
      • 19.8.6.2.5. By Distribution Channel

20. Market Structure Analysis

• 20.1. Market Analysis by Tier of Companies
• 20.2. Market Share Analysis of Top Players (%)
• 20.3. Market Presence Analysis
  • 20.3.1. Regional Footprint of Players
  • 20.3.2. Product Footprint of Players
  • 20.3.3. Channel Footprint of Players

21. Competition Analysis

• 21.1. Competition Dashboard
• 21.2. Key Development Analysis
• 21.3. Branding and Promotional Strategies, By Key Players
• 21.4. Competition Deep Dive
  • 21.4.1. Zoetis Animal Healthcare
    • 21.4.1.1. Overview
    • 21.4.1.2. Product Portfolio
    • 21.4.1.3. Key Financials
    • 21.4.1.4. Sales Footprint
    • 21.4.1.5. SWOT Analysis
    • 21.4.1.6. Strategy Overview
      • 21.4.1.6.1. Marketing Strategies
      • 21.4.1.6.2. Channel Strategies
      • 21.4.1.6.3. Product Strategies
  • 21.4.2. Merck and Co.Inc. (US)
    • 21.4.2.1. Overview
    • 21.4.2.2. Product Portfolio
    • 21.4.2.3. Key Financials
    • 21.4.2.4. Sales Footprint
    • 21.4.2.5. SWOT Analysis
    • 21.4.2.6. Strategy Overview
      • 21.4.2.6.1. Marketing Strategies
      • 21.4.2.6.2. Channel Strategies
      • 21.4.2.6.3. Product Strategies
  • 21.4.3. Boehringer Ingelheim GmbH
    • 21.4.3.1. Overview
    • 21.4.3.2. Product Portfolio
    • 21.4.3.3. Key Financials
    • 21.4.3.4. Sales Footprint
    • 21.4.3.5. SWOT Analysis
    • 21.4.3.6. Strategy Overview
      • 21.4.3.6.1. Marketing Strategies
      • 21.4.3.6.2. Channel Strategies
      • 21.4.3.6.3. Product Strategies
  • 21.4.4. Elanco Animal Health Incorporated
    • 21.4.4.1. Overview
    • 21.4.4.2. Product Portfolio
    • 21.4.4.3. Key Financials
    • 21.4.4.4. Sales Footprint
    • 21.4.4.5. SWOT Analysis
    • 21.4.4.6. Strategy Overview
      • 21.4.4.6.1. Marketing Strategies
      • 21.4.4.6.2. Channel Strategies
      • 21.4.4.6.3. Product Strategies
  • 21.4.5. Bayer AG
    • 21.4.5.1. Overview
    • 21.4.5.2. Product Portfolio
    • 21.4.5.3. Key Financials
    • 21.4.5.4. Sales Footprint
    • 21.4.5.5. SWOT Analysis
    • 21.4.5.6. Strategy Overview
      • 21.4.5.6.1. Marketing Strategies
      • 21.4.5.6.2. Channel Strategies
      • 21.4.5.6.3. Product Strategies
  • 21.4.6. Vetoquinol S.A.
    • 21.4.6.1. Overview
    • 21.4.6.2. Product Portfolio
    • 21.4.6.3. Key Financials
    • 21.4.6.4. Sales Footprint
    • 21.4.6.5. SWOT Analysis
    • 21.4.6.6. Strategy Overview
      • 21.4.6.6.1. Marketing Strategies
      • 21.4.6.6.2. Channel Strategies
      • 21.4.6.6.3. Product Strategies
  • 21.4.7. Dechra Pharmaceuticals PLC
    • 21.4.7.1. Overview
    • 21.4.7.2. Product Portfolio
    • 21.4.7.3. Key Financials
    • 21.4.7.4. Sales Footprint
    • 21.4.7.5. SWOT Analysis
    • 21.4.7.6. Strategy Overview
      • 21.4.7.6.1. Marketing Strategies
      • 21.4.7.6.2. Channel Strategies
      • 21.4.7.6.3. Product Strategies
  • 21.4.8. Virbac SA
    • 21.4.8.1. Overview
    • 21.4.8.2. Product Portfolio
    • 21.4.8.3. Key Financials
    • 21.4.8.4. Sales Footprint
    • 21.4.8.5. SWOT Analysis
    • 21.4.8.6. Strategy Overview
      • 21.4.8.6.1. Marketing Strategies
      • 21.4.8.6.2. Channel Strategies
      • 21.4.8.6.3. Product Strategies
  • 21.4.9. IDEXX Laboratories, Inc.
    • 21.4.9.1. Overview
    • 21.4.9.2. Product Portfolio
    • 21.4.9.3. Key Financials
    • 21.4.9.4. Sales Footprint
    • 21.4.9.5. SWOT Analysis
    • 21.4.9.6. Strategy Overview
      • 21.4.9.6.1. Marketing Strategies
      • 21.4.9.6.2. Channel Strategies
      • 21.4.9.6.3. Product Strategies
  • 21.4.10. Ceva Sante Animale
    • 21.4.10.1. Overview
    • 21.4.10.2. Product Portfolio
    • 21.4.10.3. Key Financials
    • 21.4.10.4. Sales Footprint
    • 21.4.10.5. SWOT Analysis
    • 21.4.10.6. Strategy Overview
      • 21.4.10.6.1. Marketing Strategies
      • 21.4.10.6.2. Channel Strategies
      • 21.4.10.6.3. Product Strategies
  • 21.4.11. Kindred Biosciences, Inc.
    • 21.4.11.1. Overview
    • 21.4.11.2. Product Portfolio
    • 21.4.11.3. Key Financials
    • 21.4.11.4. Sales Footprint
    • 21.4.11.5. SWOT Analysis
    • 21.4.11.6. Strategy Overview
      • 21.4.11.6.1. Marketing Strategies
      • 21.4.11.6.2. Channel Strategies
      • 21.4.11.6.3. Product Strategies
  • 21.4.12. Phirbo Animal Health
    • 21.4.12.1. Overview
    • 21.4.12.2. Product Portfolio
    • 21.4.12.3. Key Financials
    • 21.4.12.4. Sales Footprint
    • 21.4.12.5. SWOT Analysis
    • 21.4.12.6. Strategy Overview
      • 21.4.12.6.1. Marketing Strategies
      • 21.4.12.6.2. Channel Strategies
      • 21.4.12.6.3. Product Strategies
  • 21.4.13. Norbrook Laboratories Limited
    • 21.4.13.1. Overview
    • 21.4.13.2. Product Portfolio
    • 21.4.13.3. Key Financials
    • 21.4.13.4. Sales Footprint
    • 21.4.13.5. SWOT Analysis
    • 21.4.13.6. Strategy Overview
      • 21.4.13.6.1. Marketing Strategies
      • 21.4.13.6.2. Channel Strategies
      • 21.4.13.6.3. Product Strategies
  • 21.4.14. Vetiquinol SA
    • 21.4.14.1. Overview
    • 21.4.14.2. Product Portfolio
    • 21.4.14.3. Key Financials
    • 21.4.14.4. Sales Footprint
    • 21.4.14.5. SWOT Analysis
    • 21.4.14.6. Strategy Overview
      • 21.4.14.6.1. Marketing Strategies
      • 21.4.14.6.2. Channel Strategies
      • 21.4.14.6.3. Product Strategies
  • 21.4.15. Neogen Corporation
    • 21.4.15.1. Overview
    • 21.4.15.2. Product Portfolio
    • 21.4.15.3. Key Financials
    • 21.4.15.4. Sales Footprint
    • 21.4.15.5. SWOT Analysis
    • 21.4.15.6. Strategy Overview
      • 21.4.15.6.1. Marketing Strategies
      • 21.4.15.6.2. Channel Strategies
      • 21.4.15.6.3. Product Strategies
  • 21.4.16. PetIQ, Inc.
    • 21.4.16.1. Overview
    • 21.4.16.2. Product Portfolio
    • 21.4.16.3. Key Financials
    • 21.4.16.4. Sales Footprint
    • 21.4.16.5. SWOT Analysis
    • 21.4.16.6. Strategy Overview
      • 21.4.16.6.1. Marketing Strategies
      • 21.4.16.6.2. Channel Strategies
      • 21.4.16.6.3. Product Strategies
  • 21.4.17. Huvepharma AD
    • 21.4.17.1. Overview
    • 21.4.17.2. Product Portfolio
    • 21.4.17.3. Key Financials
    • 21.4.17.4. Sales Footprint
    • 21.4.17.5. SWOT Analysis
    • 21.4.17.6. Strategy Overview
      • 21.4.17.6.1. Marketing Strategies
      • 21.4.17.6.2. Channel Strategies
      • 21.4.17.6.3. Product Strategies
  • 21.4.18. Chanelle Pharma Group Limited
    • 21.4.18.1. Overview
    • 21.4.18.2. Product Portfolio
    • 21.4.18.3. Key Financials
    • 21.4.18.4. Sales Footprint
    • 21.4.18.5. SWOT Analysis
    • 21.4.18.6. Strategy Overview
      • 21.4.18.6.1. Marketing Strategies
      • 21.4.18.6.2. Channel Strategies
      • 21.4.18.6.3. Product Strategies
  • 21.4.19. Kepro
    • 21.4.19.1. Overview
    • 21.4.19.2. Product Portfolio
    • 21.4.19.3. Key Financials
    • 21.4.19.4. Sales Footprint
    • 21.4.19.5. SWOT Analysis
    • 21.4.19.6. Strategy Overview
      • 21.4.19.6.1. Marketing Strategies
      • 21.4.19.6.2. Channel Strategies
      • 21.4.19.6.3. Product Strategies
  • 21.4.20. Biogenesis Bago
    • 21.4.20.1. Overview
    • 21.4.20.2. Product Portfolio
    • 21.4.20.3. Key Financials
    • 21.4.20.4. Sales Footprint
    • 21.4.20.5. SWOT Analysis
    • 21.4.20.6. Strategy Overview
      • 21.4.20.6.1. Marketing Strategies
      • 21.4.20.6.2. Channel Strategies
      • 21.4.20.6.3. Product Strategies

22. Assumptions and Acronyms Used

23. Research Methodology